Alla Lisyanskaya

Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

Kathleen N. Moore, Nicoletta Colombo, Giovanni Scambia et al. · New England Journal of Medicine · 2018 · 2.8K citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

Éric Pujade-Lauraine, Jonathan A. Ledermann, Frédèric Selle et al. · The Lancet Oncology · 2017 · 1.9K citations

Pharmacy, Oncology, Pharmacotherapy +14

Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study

Ursula A. Matulonis, Ronnie Shapira‐Frommer, Alessandro D. Santin et al. · Annals of Oncology · 2019 · 840 citations · Full text

Medicine, Oncology, Pharmacology +15

Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial

Paul DiSilvestro, Susana Banerjee, Nicoletta Colombo et al. · Journal of Clinical Oncology · 2022 · 475 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial

Andrés Poveda, Anne Floquet, Jonathan A. Ledermann et al. · The Lancet Oncology · 2021 · 416 citations · Full text

Medicine, Oncology, Pharmacology +15